SYS1-DBNDD2: A Potential Drug Target and Biomarker (G767557)

SYS1-DBNDD2: A Potential Drug Target and Biomarker

SYS1-DBNDD2 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a part of the superfamily of RNA-protein adaptor proteins, known as DBNDZ domain containing proteins (DBNDZPs). The DBNDZPs are a family of transmembrane proteins that have been characterized for their ability to form RNA-protein complexes, thereby participating in various cellular processes, including signaling pathways, DNA replication, and protein-protein interactions. SYS1-DBNDD2 is one of the DBNDZPs that has been identified and studied extensively.

The SYS1-DBNDD2 protein is composed of a unique open-loop structure that consists of a 176-amino acid protein core, a 134-amino acid transmembrane region, and a 26-amino acid C-terminal tail. The protein is expressed in various tissues of the body and has been shown to be involved in various physiological processes, including cell signaling, DNA replication, and protein-protein interactions.

SYS1-DBNDD2 as a Drug Target

SYS1-DBNDD2 has been identified as a potential drug target due to its involvement in various signaling pathways. The DBNDZPs have been shown to play important roles in intracellular signaling, including the regulation of cell adhesion, migration, and survival. SYS1-DBNDD2 has been shown to be involved in the regulation of theNotch signaling pathway, a well-established mode of cell-to-cell signaling that plays a crucial role in the development and maintenance of tissues.

SYS1-DBNDD2 has been shown to regulate the Notch signaling pathway by interacting with the Notch receptor, a transmembrane protein that plays a central role in the regulation of cellular processes, including stem cell self-renewal, differentiation, and survival. SYS1-DBNDD2 has been shown to form a complex with the Notch receptor, thereby modulating its activity and influencing the behavior of cells.

SYS1-DBNDD2 has also been shown to play a role in the regulation of cell signaling pathways that are involved in the development and progression of cancer. For example, SYS1-DBNDD2 has been shown to be involved in the regulation of the TGF-β signaling pathway, a well-established mode of cell-to-cell signaling that plays a crucial role in the development and progression of many types of cancer.

SYS1-DBNDD2 as a Biomarker

SYS1-DBNDD2 has also been shown to be a potential biomarker for various diseases, including cancer. The DBNDZPs have been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and survival, which are important for the development and progression of cancer. Therefore, SYS1-DBNDD2 has been considered as a potential biomarker for cancer diagnosis and treatment.

SYS1-DBNDD2 has been shown to be involved in the regulation of cell adhesion, which is a critical process for the development and progression of cancer. For example, SYS1-DBNDD2 has been shown to be involved in the regulation of cell-cell adhesion, a process that is critical for the development of cancer stem cells. SYS1-DBNDD2 has also been shown to be involved in the regulation of cell migration, which is a critical process for the development and progression of cancer.

SYS1-DBNDD2 has also been shown to be involved in the regulation of

Protein Name: SYS1-DBNDD2 Readthrough (NMD Candidate)

The "SYS1-DBNDD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYS1-DBNDD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SYT1 | SYT10 | SYT11 | SYT12 | SYT13 | SYT14 | SYT15 | SYT15B | SYT16 | SYT17 | SYT2 | SYT3 | SYT4 | SYT5 | SYT6 | SYT7 | SYT8 | SYT9 | SYTL1 | SYTL2 | SYTL3 | SYTL4 | SYTL5 | SYVN1 | SZRD1 | SZRD1P1 | SZT2 | T-Box transcription factor (TBX) | T-Type Calcium Channel | TAAR1 | TAAR2 | TAAR3P | TAAR5 | TAAR6 | TAAR8 | TAAR9 | TAB1 | TAB2 | TAB2-AS1 | TAB3 | TAC1 | TAC3 | TAC4 | TACC1 | TACC2 | TACC3 | Tachykinin Receptor | TACO1 | TACR1 | TACR2 | TACR3 | TACSTD2 | TADA1 | TADA2A | TADA2B | TADA3 | TAF1 | TAF10 | TAF11 | TAF11L2 | TAF11L3 | TAF12 | TAF12-DT | TAF13 | TAF15 | TAF1A | TAF1A-AS1 | TAF1B | TAF1C | TAF1D | TAF1L | TAF2 | TAF3 | TAF4 | TAF4B | TAF5 | TAF5L | TAF5LP1 | TAF6 | TAF6L | TAF7 | TAF7L | TAF8 | TAF9 | TAF9B | TAFA1 | TAFA2 | TAFA3 | TAFA4 | TAFA5 | TAFAZZIN | TAGAP | TAGAP-AS1 | TAGLN | TAGLN2 | TAGLN3 | TAK1 | TAL1 | TAL2 | TALDO1